Blog Category: Certified Activity

Expanding Options for Immune Checkpoint Inhibitors in Front-Line Advanced/Recurrent Endometrial Cancer

Recent advances in the treatment of gynecologic cancers are promising, and education is needed to ensure that both oncology and primary care clinicians, including OB/GYNs, have a thorough knowledge of biomarkers, current and emerging therapies, and how the latest clinical …

Demystifying Chronic Inflammatory Demyelinating Polyneuropathy (CIDP): A Journal Club Exploring Guidelines and Novel Solutions

Treatment guidelines for chronic inflammatory demyelinating polyneuropathy (CIDP), an autoimmune neuro-muscular condition impacting the myelin that insulates and protects peripheral nerves causing mobility and sensory impairment, have been in place for many years with new treatment approvals being scarce. Newly …

Revolutionizing Pain Care: Applying the Latest Updates in Opioid REMS Education to Your Practice

The 2022 Clinical Practice Guideline for Prescribing Opioids for Pain, developed by the Centers for Disease Control and Prevention (CDC), was introduced as an update to the 2016 CDC Guideline for Prescribing Opioids for Chronic Pain. This update aimed to …

Confusion on the Horizon: Novel Therapies Emerging for the Treatment of Endometrial Cancer

Recent advances in the treatment of gynecologic cancers are promising, and education is needed to ensure that both oncology and primary care clinicians, including OB/GYNs, have a thorough knowledge of biomarkers, current and emerging therapies, and how the latest clinical …

The When and How of Maintenance Therapy in Endometrial Cancer

Recent advances in the treatment of gynecologic cancers are promising, and education is needed to ensure that both oncology and primary care clinicians, including OB/GYNs, have a thorough knowledge of biomarkers, current and emerging therapies, and how the latest clinical …

Adverse Events in the New Age of Front-line Combination Approaches in Advanced Gynecologic Cancers

Immune checkpoint inhibitors (ICIs), PARP inhibitors, VEGF inhibitors, kinase inhibitors, and chemotherapy are all being used in various combinations for the treatment of endometrial and ovarian cancers.  As these new combinations seek to further improve and enhance the efficacy of …

Clinical Pathways in T2D Care: Overcoming Inertia, Implementing Innovation

Clinicians treating patients with T2D need to know how to choose and optimally use incretin therapies that have activity against common comorbidities in T2D, including obesity and CVD. Over the past decade there have been several new classes of drugs …

Deciphering Patient Selection Related to Current and Emerging Amyloid-Targeting Therapies (ATTs)

The emerging class of amyloid-targeting therapies (ATTs) are at the forefront of innovative approaches that promise to alter the course of Alzheimer’s disease (AD). However, the translation of these scientific advancements into clinical practice necessitates a well-informed clinical workforce adept …

Untangling the Data: pTau and Neurofibrillary Tangles as Part of Early Alzheimer’s Detection

Alzheimer’s disease (AD) presents a growing challenge in contemporary health care, with escalating prevalence and a significant burden imposed on patients, families, and health care systems globally. Early and accurate diagnosis of AD is essential for effective support and treatment. …